Savolitinib for Treating Brain and Leptomeningeal Metastases in Non-Small Cell Lung Cancer: A Case Study
-
By
-
Xuejiao Qi
-
Zhijiao Song
-
Junying He
-
Hui Bu
-
April 24, 2026
-
Clinical Scorecard: Savolitinib for Treating Brain and Leptomeningeal Metastases in Non-Small Cell Lung Cancer: A Case Study
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Patients with NSCLC harboring METex14 skipping mutations and CNS metastases. |
| Care Setting | |
Key Highlights
- The patient achieved an intracranial partial response after treatment with savolitinib.
- The patient's overall survival post-diagnosis of BM and LM was 11 months.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Follow-up brain MRI is recommended for monitoring metastasis, ideally every 2-3 months.
Risks
Patient & Prescribing Data
Savolitinib demonstrated promising intracranial activity with a manageable safety profile, including mild nausea and vomiting.
Clinical Best Practices
- Utilize NGS for precise identification of genetic alterations in CNS metastases.
- Consider the patient's performance status and preferences when recommending treatment options.
- Perform NGS testing prior to treatment initiation to guide therapy.
References
